NeoProfen FDA Approval History
FDA Approved: Yes (First approved April 13, 2006)
Brand name: NeoProfen
Generic name: ibuprofen lysine
Dosage form: Injection
Company: Farmacon-IL, LLC
Treatment for: Patent Ductus Arteriosus
NeoProfen is an intravenous formulation of ibuprofen lysine indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, who are no more than 32 weeks gestational age when usual medical management is ineffective.
Development Timeline for NeoProfen
|Apr 13, 2006||NeoProfen Approved - Farmacon-IL, LLC - Treatment for Patent Ductus Arteriosus|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.